Biological use influences the impact of inflammation on risk of major adverse cardiovascular events in rheumatoid arthritis
George Athanasios Karpouzas,Sarah R Ormseth,Piet Leonardus Cornelis Maria van Riel,Miguel A Gonzalez-Gay,Alfonso Corrales,Solbritt Rantapää-Dahlqvist,Petros P Sfikakis,Patrick Dessein,Linda Tsang,Carol Hitchon,Hani El-Gabalawy,Virginia Pascual-Ramos,Irazú Contreras-Yáñez,Iris J Colunga-Pedraza,Dionicio Angel Galarza-Delgado,Jose Ramon Azpiri-Lopez,Anne Grete Semb,Durga Prasanna Misra,Ellen-Margrethe Hauge,George Kitas,Karpouzas,G. A.,Ormseth,S. R.,van Riel,P. L. C. M.,Gonzalez-Gay,M. A.,Corrales,A.,Rantapää-Dahlqvist,S.,Sfikakis,P. P.,Dessein,P.,Tsang,L.,Hitchon,C.,El-Gabalawy,H.,Pascual-Ramos,V.,Contreras-Yanez,I.,Colunga-Pedraza,I. J.,Galarza-Delgado,D. A.,Azpiri-Lopez,J. R.,Semb,A. G.,Misra,D. P.,Hauge,E.-M.,Kitas,G.
DOI: https://doi.org/10.1136/rmdopen-2024-004546
2024-07-24
RMD Open
Abstract:Objectives Chronic inflammation promotes cardiovascular risk in rheumatoid arthritis (RA). Biological disease-modifying antirheumatic drugs (bDMARDs) improve disease activity and cardiovascular disease outcomes. We explored whether bDMARDs influence the impact of disease activity and inflammatory markers on long-term cardiovascular risk in RA. Methods We studied 4370 participants without cardiovascular disease in a 10-country observational cohort of patients with RA. Endpoints were (1) major adverse cardiovascular events (MACE) encompassing myocardial infarction, stroke and cardiovascular death; and (2) any ischaemic cardiovascular events (iCVE) including MACE plus revascularisation, angina, transient ischaemic attack and peripheral arterial disease. Results Over 26 534 patient-years, 239 MACE and 362 iCVE occurred. The interaction between 28-joint Disease Activity Score with C-reactive protein (DAS28-CRP) and bDMARD use was significant for MACE (p=0.017), suggesting the effect of DAS28-CRP on MACE risk differed among bDMARD users (n=515) and non-users (n=3855). DAS28-CRP (per unit increase) is associated with MACE risk in bDMARD non-users (HR 1.21 (95% CI 1.07 to 1.37)) but not users (HR 0.69 (95% CI 0.40 to 1.20)). The interaction between CRP (per log unit increase) and bDMARD use was also significant for MACE (p=0.011). CRP associated with MACE risk in bDMARD non-users (HR 1.16 (95% CI 1.04 to 1.30)), but not users (HR 0.65 (95% CI 0.36 to 1.17)). No interaction was observed between bDMARD use and DAS28-CRP (p=0.167) or CRP (p=0.237) for iCVE risk. Conclusions RA activity and inflammatory markers associated with risk of MACE in bDMARD non-users but not users suggesting the possibility of biological-specific benefits locally on arterial wall independently of effects on systemic inflammation.
rheumatology